Abbott Laboratories (NYSE: ABT) CEO Robert Ford, while speaking at the HLTH conference in Las Vegas, outlined the company's strategic move into the consumer wearables market.
Tempest Therapeutics Inc (NASDAQ: TPST) released new and updated results from the planned data analysis of an ongoing Phase 1b/2 study of TPST-1120 in the first-line treatment of patients with unresectable or
Mallinckrodt plc (OTC: MNKTQ), one of the largest manufacturers of prescription opioids in the U.S., has secured court approval for a plan that erases over $1 billion in payments intended for peo
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to